Is routine histological tissue sampling during endoscopic dacryocystorhinostomy advantageous? A retrospective analysis of 213 patients 1 
| INTRODUCTION
The prevalence of tumours of the lacrimal duct system is very low (1.43%). 1 Tumours developing in this region cover a large spectrum of entities that fall into two categories: primary epithelial neoplasms and primary non-epithelial neoplasms. The typical symptoms of a dysfunction of the lacrimal duct system, such as epiphora, secretion and swelling of the lacrimal sac, can be caused by stenosis or inflammation as well as by benign and malignant proliferative diseases of the tear duct system. Malignant disease must always be suspected when there are clinical signs such as telangiectasias over the swelling and serous-sanguineous secretion. [2] [3] [4] [5] Besides primary tumours, in rare cases, metastases or secondary tumours can also develop in the lacrimal duct system. In most cases, neoplasms of the tear duct system are detected very late and often accidentally. 2, 6 To restore patency to a stenotic lacrimal duct system in patients who present with chronic or intermittent epiphora, endoscopic dacryocystorhinostomy (DCR) can be considered as the golden standard of treatment. In our department, tissue was not routinely sampled for histological examination during endoscopic DCR. In the literature, the relevance of routine lacrimal sac biopsy is discussed controversially, although malignant proliferative disease cannot be excluded with certainty without histological examination. Merkonidis et al. 7 show that a biopsy is only necessary if diseases other than chronic inflammation are suspected pre-or intraoperatively. In contrast, Koturovic et al. 8 postulated that a routine biopsy of the lacrimal sac is highly valuable, as a previously suspected diagnosis can be confirmed or unexpected diseases revealed without further inconvenience to the patient.
7,8

| MATERIALS AND METHODS
In this study, we analysed data from all 364 patients referred to the The aim of this retrospective study was to determine the usefulness of routine tissue collection during surgery for histological examination. On the basis of the histopathological reports, we calculated the rate of incidental findings of an occult benign or malignant tumour that was not suspected before or during surgery.
| Ethical considerations
The study was approved by the institutional review board of the Medical University of Graz (approval number: 27-192 ex 14/15) and complies with the Declaration of Helsinki.
| Statistical analysis
The data underwent descriptive and frequency distribution analysis
with SPSS (IBM SPSS Statistics 23). The Kolmogorov-Smirnov test
was performed to test for normal distribution. The following parameters were analysed with cross-tabulation: tissue samples (yes/no) and incidental findings of benign or malignant proliferative disease (yes/ no).
| RESULTS
All DCRs (N = 364) were statistically analysed. The majority of patients were female (N = 240, 65.9%); the average age of all patients was 56 years (SD: 22 years), and the average follow-up period was 13.1 months (SD: 23.7 months). The most frequent pre-surgical diagnosis was acquired dacryostenosis (70.1%; 255 patients);
acute dacryocystitis was suspected in 46 patients (12.6%) and the chronic form in 47 (12.9%). The remaining less frequently suspected diagnoses were dacryolithiasis, dacryocele, lacrimal sac abscess, epiphora and orbital phlegmon. In none of the referred cases was a tumour suspected prior to surgery.
During surgery, tissue samples were taken from 213 of 364 patients and examined histologically (58.5%). In the remaining cases (151, 41.5%), no tissue was excised as the nasolacrimal sac was only opened, without partial resection of its medial wall. This was because various surgeons had used different techniques in this retrospective study. Proliferative disease was detected in five (2.3%) of The patient with the poorly differentiated non-keratinising squamous cell carcinoma required radical surgery and radiation with a total dose of 60 gray, followed by 10-month recurrence-free survival. Documentation did not indicate death due to the malignant disease. Koturovic et al. 8 postulated that a routine biopsy of the lacrimal sac is of high value as a previously suspected diagnosis can be confirmed or unexpected diseases revealed without inconveniencing patients.
| DISCUSSION
Given the considerable rates of incidental tumour findings, biopsies should always be taken, even during revision surgeries. For tonsillectomies, Booth et al. 11 described an incidental finding of occult haematologic disease with a rate of 0.5%, thus justifying routine histological work-up after tonsillectomy.
Considering the whole study population (N = 364), the rate of incidental tumour finding would be 1.4%, given the fact that the patients without intraoperative tissue sampling did not show a tumour in the follow-up period. A shortcoming of the study is its retrospective character. Upon analysis of the surgical reports, we found that no nasolacrimal mucosa was harvested for histology when the surgeon had only opened the nasolacrimal sac without partially resecting its medial wall. However, in the other 213 patients, in whom the nasolacrimal sac was partially resected medially and the mucosa marsupialised with the nasal mucosa, the harvested tissue was sent for histology. In none of these cases did the surgeon suspect a proliferative disease intraoperatively.
| CONCLUSION
In spite of the relatively low overall prevalence of malignant tumours of the nasolacrimal duct, the rate of incidental tumour findings in the present study justifies routine histological work-up, particularly as tissue sampling during DCR does not in any way inconvenience the patient. There are over 350 000 cochlear implant recipients worldwide 1 and despite the very high reliability, these devices do occasionally fail.
CONFLI CT OF INTEREST
Internationally, device failure rates have been reported to vary between 3% and 5% in large centre studies. 
Auditory problems
The integrity testing is performed at the endpoint of troubleshooting any suspected problem. The testing is conducted onsite by the manufacturer using specific equipment that can connect and assess the implant in-situ. It is a time-consuming process as it often requires an additional visit by the manufacturer to the clinic.
CORRESPONDENCE: OUR EXPERIENCE
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